Company: ZVRA
Filing Date: 2025-04-24
Form Type: PRRN14A
Source: 0000897069-25-000871
Chunk: 10

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-04-24
Form: PRRN14A
Chunk 10
---
 the Board at the Annual Meeting. Mr. DeBoom expressed that Mr. Mangless would support the Board’s qualified nominee, including either of Ms. Favorito or Wendy Dixon, Ph.D. (the two incumbent directors whose terms were set to expire at the Annual Meeting and who are nominated by the Board for re-election at the Annual Meeting), provided that the Board also supports Dr. Mickle (the “ Updated Mangless Offer”). On March 21, 2025, Mr. DeBoom sent an email to Mr. Thompson, copying a representative of Latham & Watkins LLP, to reiterate the Updated Mangless Offer. On March 24, 2025, Mr. Thompson sent an email to Mr. DeBoom, copying a representative of Latham & Watkins LLP, providing Mr. Mangless with the required notification of the Company’s nominees for election at the Annual Meeting, Ms. Favorito and Dr. Dixon, pursuant to Rule 14a-19(d) under the Exchange Act. On March 31, 2025, the Company filed a preliminary proxy statement with the U.S. Securities and Exchange Commission (“ SEC”) in connection with the 2025 Annual Meeting. On April 10, 2025, the Proponent filed a preliminary proxy statement with the SEC in connection with the Annual Meeting followed by a press release to the stockholders of the Company. On April 16, 2025, the Proponent filed an amended and restated preliminary proxy statement with the SEC in connection with the Annual Meeting. On April 21, 2025, the Company filed a definitive proxy statement with the SEC in connection with the 2025 Annual Meeting. On April 24, 2025, the Proponent filed an amended and restated preliminary proxy statement with the SEC in connection with the Annual Meeting. 7 REASONS FOR OUR SOLICITATION We believe Zevra is dramatically undervalued and our goal is to help the Company reach its full potential. Zevra has a troubling history of underperformance andpoor corporate governance practices and the stockholders have long suffered under the leadership of the current Board of Directors. While the election at Zevra’s 2023 Annual Meeting of Stockholders brought about important change, including new leadership with extensive commercial experience, I believe that other important governance issues remain unresolved, to the detriment of all Zevra stockholders. Namely, I believe these unresolved issues include the Company’s governance practices of having a classified board and the use of a